These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30536988)

  • 1. Nigral iron deposition in common tremor disorders.
    Homayoon N; Pirpamer L; Franthal S; Katschnig-Winter P; Kögl M; Seiler S; Wenzel K; Hofer E; Deutschmann H; Fazekas F; Langkammer C; Ropele S; Schmidt R; Schwingenschuh P
    Mov Disord; 2019 Jan; 34(1):129-132. PubMed ID: 30536988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different iron deposition patterns in akinetic/rigid-dominant and tremor-dominant Parkinson's disease.
    Xiong W; Li LF; Huang L; Liu Y; Xia ZC; Zhou XX; Tang BS; Guo JF; Lei LF
    Clin Neurol Neurosurg; 2020 Nov; 198():106181. PubMed ID: 33022525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X
    Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
    Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
    Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low plasma serotonin linked to higher nigral iron in Parkinson's disease.
    Jellen LC; Lewis MM; Du G; Wang X; Galvis MLE; Krzyzanowski S; Capan CD; Snyder AM; Connor JR; Kong L; Mailman RB; Brundin P; Brundin L; Huang X
    Sci Rep; 2021 Dec; 11(1):24384. PubMed ID: 34934078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study.
    Guan X; Xuan M; Gu Q; Xu X; Huang P; Wang N; Shen Z; Xu J; Luo W; Zhang M
    J Magn Reson Imaging; 2017 May; 45(5):1335-1342. PubMed ID: 27545971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks.
    Wen J; Guo T; Wu J; Bai X; Zhou C; Wu H; Liu X; Chen J; Cao Z; Gu L; Pu J; Zhang B; Zhang M; Guan X; Xu X
    J Parkinsons Dis; 2022; 12(8):2479-2492. PubMed ID: 36336939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
    Saikiran P;
    Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
    Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F
    PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.